Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.23.1
SEGMENT INFORMATION
 6 Months Ended
Apr. 30, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and six months ended April 30, 2023 and 2022 and as of April 30, 2023 and October 31, 2022, in thousands:

  

    2023     2022     2023     2022  
    For the Three Months Ended
April 30,		     For the Six Months Ended
April 30,		  
    2023     2022     2023     2022  
Net income/(loss):                                
CAR-T Therapeutics   $ (997 )   $ (1,399 )   $ (1,908 )   $ (3,010 )
Cancer Vaccines     (913 )     (1,423 )     (1,871 )     (2,780 )
Anti-Viral Therapeutics     (416 )     (757 )     (898 )     (1,661 )
Other     19     (9 )     16     (16 )
Total   $ (2,307 )   $ (3,588 )   $ (4,661 )   $ (7,467 )
                                 
Total operating costs and expenses   $ 2,770     $ 3,589     $ 5,326     $ 7,469  
Less non-cash stock-based compensation     (1,227 )     (1,745 )     (2,290 )     (4,099 )
Operating costs and expenses excluding non-cash stock-based compensation   $ 1,543     $ 1,844     $ 3,036     $ 3,370  
Operating costs and expenses excluding non-cash stock-based compensation:                                
CAR-T Therapeutics   $ 620     $ 733     $ 1,218     $ 1,402  
Cancer Vaccines     523       716       1,111       1,196  
Anti-Viral Therapeutics     212       388       517       760  
Other     188       7       190       12  
Total   $ 1,543     $ 1,844     $ 3,036     $ 3,370  

 

    April 30,
2023		     October 31,
2022		  
Total assets:                
CAR-T Therapeutics   $ 11,682     $ 16,921  
Cancer Vaccines     10,638       9,442  
Anti-Viral Therapeutics    

4,953

       3,811  
Other    

326

       238  
Total   $ 27,599     $ 30,412  

 

Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000 for the three and six months ended April 30, 2023 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.